Author's Accepted Manuscript

Ranolazine Terminates Atrial Flutter and Fibrillation in a Canine Model

Ashish A. Bhimani MD, Tomoo Yasuda MD, Shervin A. Sadrpour MD, Celeen M. Khrestian BS, Seungyup Lee PhD, Dewan Zeng PhD, Luiz Belardinelli MD, Albert L. Waldo MD, FHRS



www.elsevier.com/locate/buildenv

PII: S1547-5271(14)00624-9

DOI: http://dx.doi.org/10.1016/j.hrthm.2014.05.038

Reference: HRTHM5801

To appear in: Heart Rhythm

Cite this article as: Ashish A. Bhimani MD, Tomoo Yasuda MD, Shervin A. Sadrpour MD, Celeen M. Khrestian BS, Seungyup Lee PhD, Dewan Zeng PhD, Luiz Belardinelli MD, Albert L. Waldo MD, FHRS, Ranolazine Terminates Atrial Flutter and Fibrillation in a Canine Model, *Heart Rhythm*, http://dx.doi.org/10.1016/j.hrthm.2014.05.038

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Ranolazine Terminates Atrial Flutter and Fibrillation in a Canine Model

Authors:

Ashish A. Bhimani, MD¹, Tomoo Yasuda, MD², Shervin A. Sadrpour, MD³, Celeen M. Khrestian, BS, Seungyup Lee, PhD, Dewan Zeng, PhD⁴, Luiz Belardinelli, MD⁴, and Albert L. Waldo, MD, FHRS

From the Division of Cardiovascular Medicine, Case Western Reserve University / University Hospitals Case Medical Center, Cleveland, Ohio

1. Present address:

University of Texas Medical Branch, Galveston, TX

2. Present address:

Fukuoka University School of Medicine, Fukuoka, Japan

3. Present address:

Mercy Heart Institute, Cincinnati, OH

4. Present address:

Gilead Sciences, Inc, Foster City, CA

This research was supported in part by a grant from Gilead Sciences, Inc. Remaining financial support was institutional.

Author conflicts of interest:

Bhimani: none; **Yasuda**: none; **Sadrpour**: none; **Khrestian**: none; **Lee**: none; **Zeng**: Gilead Sciences employee (salary, stock, patents on ranolazine); **Belardinelli**: Gilead Sciences employee (salary, stock, patents on ranolazine); **Waldo**: research contract (Gilead Sciences), consulting (Biotronik, St. Jude Medical, Daiichi Sankyo, Biosense Webster, Sanofi, Gilead Sciences, CardioInsight, AtriCure, Pfizer, and ChanRx, speaker (Sanofi, Janssen, Pfizer, Bristol-Myers Squibb).

Address for all correspondence:

Ashish A. Bhimani, MD

University of Texas Medical Branch

Galveston, TX

Phone: 773-469-8294

Email: ashish.bhimani@gmail.com

Word Counts:

Abstract Word Count: 245

Manuscript Word Count: 4,950 (including abstract)

Download English Version:

https://daneshyari.com/en/article/5960492

Download Persian Version:

https://daneshyari.com/article/5960492

<u>Daneshyari.com</u>